Patent ID: 6417158
Filing Date: 2002-07-09
Classification: A61K,C07K,C12Q,G01N,Y02A,Y10S

Abstract:
A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide which is nonglycosylated or has a CHO cell-derived glycosylation pattern has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:A) DNA comprising the sequence: R2â€ƒâ€ƒGATâ€ƒAGTâ€ƒGTGâ€ƒTGTâ€ƒCCCâ€ƒCAAâ€ƒGGAâ€ƒAAAâ€ƒTATâ€ƒATCâ€ƒCAC CCTâ€ƒCAAâ€ƒAATâ€ƒAATâ€ƒTCGâ€ƒATTâ€ƒTGCâ€ƒTGTâ€ƒACCâ€ƒAAGâ€ƒTGCâ€ƒCAC AAAâ€ƒGGAâ€ƒACCâ€ƒTACâ€ƒTTGâ€ƒTACâ€ƒAATâ€ƒGACâ€ƒTGTâ€ƒCCAâ€ƒGGCâ€ƒCCG GGGâ€ƒCAGâ€ƒGATâ€ƒACGâ€ƒGACâ€ƒTGCâ€ƒAGGâ€ƒGAGâ€ƒTGTâ€ƒGAGâ€ƒAGCâ€ƒGGC TCCâ€ƒTTCâ€ƒACCâ€ƒGCTâ€ƒTCAâ€ƒGAAâ€ƒAACâ€ƒCACâ€ƒCTCâ€ƒAGAâ€ƒCACâ€ƒTGC CTCâ€ƒAGCâ€ƒTGCâ€ƒTCCâ€ƒAAAâ€ƒTGCâ€ƒCGAâ€ƒAAGâ€ƒGAAâ€ƒATGâ€ƒGGTâ€ƒCAG GTGâ€ƒGAGâ€ƒATCâ€ƒTCTâ€ƒTCTâ€ƒTGCâ€ƒACAâ€ƒGTGâ€ƒGACâ€ƒCGGâ€ƒGACâ€ƒACC GTGâ€ƒTGTâ€ƒGGCâ€ƒTGCâ€ƒAGGâ€ƒAAGâ€ƒAACâ€ƒCAGâ€ƒTACâ€ƒCGGâ€ƒCATâ€ƒTAT TGGâ€ƒAGTâ€ƒGAAâ€ƒAACâ€ƒCTTâ€ƒTTCâ€ƒCAGâ€ƒTGCâ€ƒTTCâ€ƒAATâ€ƒTGCâ€ƒAGC CTCâ€ƒTGCâ€ƒCTCâ€ƒAATâ€ƒGGGâ€ƒACCâ€ƒGTGâ€ƒCACâ€ƒCTCâ€ƒTCCâ€ƒTGCâ€ƒCAG GAGâ€ƒAAAâ€ƒCAGâ€ƒAACâ€ƒACCâ€ƒGTGâ€ƒTGCâ€ƒACCâ€ƒTGCâ€ƒCATâ€ƒGCAâ€ƒGGT TTCâ€ƒTTTâ€ƒCTAâ€ƒAGAâ€ƒGAAâ€ƒAACâ€ƒGAGâ€ƒTGTâ€ƒGTCâ€ƒTCCâ€ƒTGTâ€ƒAGT AACâ€ƒTGTâ€ƒAAGâ€ƒAAAâ€ƒAGCâ€ƒCTGâ€ƒGAGâ€ƒTGCâ€ƒACGâ€ƒAAGâ€ƒTTGâ€ƒTGC CTAâ€ƒCCCâ€ƒCAGâ€ƒATTâ€ƒGAGâ€ƒAAT,or a C- and/or N-terminally shortened sequence thereof, wherein R2 is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved in vivo; andB) DNA comprising the sequence: R2â€ƒâ€ƒGATâ€ƒAGTâ€ƒGTGâ€ƒTGTâ€ƒCCCâ€ƒCAAâ€ƒGGAâ€ƒAAAâ€ƒTATâ€ƒATCâ€ƒCAC CCTâ€ƒCAAâ€ƒAATâ€ƒAATâ€ƒTCGâ€ƒATTâ€ƒTGCâ€ƒTGTâ€ƒACCâ€ƒAAGâ€ƒTGCâ€ƒCAC AAAâ€ƒGGAâ€ƒACCâ€ƒTACâ€ƒTTGâ€ƒTACâ€ƒAATâ€ƒGACâ€ƒTGTâ€ƒCCAâ€ƒGGCâ€ƒCCG GGGâ€ƒCAGâ€ƒGATâ€ƒACGâ€ƒGACâ€ƒTGCâ€ƒAGGâ€ƒGAGâ€ƒTGTâ€ƒGAGâ€ƒAGCâ€ƒGGC TCCâ€ƒTTCâ€ƒACCâ€ƒGCTâ€ƒTCAâ€ƒGAAâ€ƒAACâ€ƒCACâ€ƒCTCâ€ƒAGAâ€ƒCACâ€ƒTGC CTCâ€ƒAGCâ€ƒTGCâ€ƒTCCâ€ƒAAAâ€ƒTGCâ€ƒCGAâ€ƒAAGâ€ƒGAAâ€ƒATGâ€ƒGGTâ€ƒCAG GTGâ€ƒGAGâ€ƒATCâ€ƒTCTâ€ƒTCTâ€ƒTGCâ€ƒACAâ€ƒGTGâ€ƒGACâ€ƒCGGâ€ƒGACâ€ƒACC GTGâ€ƒTGTâ€ƒGGCâ€ƒTGCâ€ƒAGGâ€ƒAAGâ€ƒAACâ€ƒCAGâ€ƒTACâ€ƒCGGâ€ƒCATâ€ƒTAT TGGâ€ƒAGTâ€ƒGAAâ€ƒAACâ€ƒCTTâ€ƒTTCâ€ƒCAGâ€ƒTGCâ€ƒTTCâ€ƒAATâ€ƒTGCâ€ƒAGC CTCâ€ƒTGCâ€ƒCTCâ€ƒAATâ€ƒGGGâ€ƒACCâ€ƒGTGâ€ƒCACâ€ƒCTCâ€ƒTCCâ€ƒTGCâ€ƒCAG GAGâ€ƒAAAâ€ƒCAGâ€ƒAACâ€ƒACCâ€ƒGTGâ€ƒTGCâ€ƒACCâ€ƒTGCâ€ƒCATâ€ƒGCAâ€ƒGGT TTCâ€ƒTTTâ€ƒCTAâ€ƒAGAâ€ƒGAAâ€ƒAACâ€ƒGAGâ€ƒTGTâ€ƒGTCâ€ƒTCCâ€ƒTGTâ€ƒAGT AACâ€ƒTGTâ€ƒAAGâ€ƒAAAâ€ƒAGCâ€ƒCTGâ€ƒGAGâ€ƒTGCâ€ƒACGâ€ƒAAGâ€ƒTTGâ€ƒTGC CTAâ€ƒCCCâ€ƒCAGâ€ƒATTâ€ƒGAGâ€ƒAATâ€ƒGTTâ€ƒAAGâ€ƒGGCâ€ƒACTâ€ƒGAGâ€ƒGAC TCAâ€ƒGGCâ€ƒACCâ€ƒACA,or a C- and/or N-terminally shortened sequence thereof, wherein R2 is absent or represents DNA coding for a polypeptide which can be cleaved in vivo;C) a DNA sequence of A or B encoding at least one conservative amino acid substitution; D) a DNA sequence of A or B encoding at least one amino acid substitution at a glycosylation site; E) a DNA sequence of A or B encoding at least one amino acid substitution at a proteolytic cleavage site; and F) a DNA sequence of A or B encoding at least one amino acid substitution at a cysteine residue.